About Beta Drugs Limited
Data last updated: 14 July 2026
Beta Drugs Limited is a public limited company based in Baddi, Himachal Pradesh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 21 September 2005, the company has been in operation for over 21 years.
Registered with ROC Himachal Pradesh under CIN L24230HP2005PLC028969. Listed on NSE: BETA.
Capital: an authorised share capital of ₹11.4 Cr and a paid-up capital of ₹11.09 Cr. Formerly known as Beta Drugs Private Limited. It is led by directors including Balwant Singh and Rohit Parti.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Village Nandpur, Baddi, Himachal Pradesh, India – 174101.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹384.83 Cr, a growth of 6.2% compared to the previous year. The net worth stands at ₹244.77 Cr. Total assets are valued at ₹495.8 Cr (up 13.65% YoY).
The company has a workforce of approximately 382 employees as per the latest available data. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand - Beta Drugs. As per MCA filings, the company has open charges of ₹57.52 Cr and satisfied charges of ₹24.23 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website betadrugslimited.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressVillage Nandpur, Baddi, Himachal Pradesh, India – 174101
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Beta Drugs Limited
Beta Drugs Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230HP2005PLC028969, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230HP2005PLC028969 | Current |
| U24230HP2005PTC028969 | Previous |
| U24230HP2005PLC028969 | Previous |
Associated Brands with Beta Drugs Limited
Beta Drugs Limited operates one associated brand: Beta Drugs. These brands represent Beta Drugs Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Developer of therapeutics for oncology and dermatology | betadrugslimited.com |
Competitors & Alternatives of Beta Drugs Limited
Brands and companies operating in the same space as Beta Drugs Limited include Jazz Pharmaceuticals, Pharmaron, C4 Therapeutics and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jazz Pharmaceuticals
|
Novel biopharmaceutical medicines are developed for unmet medical needs. | Dublin, Ireland, Ireland | 2003 |
Pharmaron
|
Drug discovery and development services for small molecules are provided. | Beijing, China, China | 2003 |
C4 Therapeutics
|
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | Cambridge, United States, United States | 2016 |
Syndax
|
Targeted therapies for cancer treatment are developed. | Waltham, United States, United States | 2005 |
Erasca
|
Small molecule therapeutics for cancer treatment are developed. | San Diego, United States, United States | 2018 |
Avidity Biosciences
|
Antibody-siRNA complexes are developed for cancer treatment. | San Diego, United States, United States | 2012 |
Mereo BioPharma
|
Therapeutics for cancer and rare diseases are developed. | London, United Kingdom, United Kingdom | 2015 |
Revolution Medicines
|
Cancer therapies are developed using selective pathway inhibitors. | Redwood City, United States, United States | 2014 |
Blueprint Medicines
|
Selective kinase inhibitors are developed for genomically defined cancers. | Cambridge, United States, United States | 2008 |
Business Activity of Beta Drugs Limited
Beta Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Beta Drugs Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Beta Drugs Limited
Beta Drugs Limited is audited by KALRA RAI & ASSOCIATES for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| KALRA RAI & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history for Beta Drugs Limited
Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Beta Drugs Limited
Beta Drugs Limited is currently managed by 10 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Balwant Singh
Also directs:
Beta Drugs Limited
|
Whole-Time Director | 01 Aug 2014 | 12 Years 0 Months | Current |
|
Rohit Parti
Also directs:
Beta Drugs Limited
|
Director | 26 Jul 2017 | 9 Years 0 Months | Current |
|
Manmohan Khanna
Also directs:
Beta Drugs Limited
|
Director | 26 Jul 2017 | 9 Years 0 Months | Current |
| Varun Batra | Managing Director | 01 Aug 2014 | 12 Years 0 Months | Current |
| Rahul Batra | Managing Director | 01 Aug 2014 | 12 Years 0 Months | Current |
|
Ashutosh Shukla
Also directs:
Beta Drugs Limited
|
Whole-Time Director | 20 Jan 2022 | 4 Years 7 Months | Current |
Financials of Beta Drugs Limited FY 2026 filings available
Beta Drugs Limited reported revenue of ₹384.83 Cr (up 6.2% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹384.83 Cr | ₹362.36 Cr |
| Other Income | ₹11.18 Cr | ₹6.44 Cr |
| Total Income | ₹396.01 Cr | ₹368.79 Cr |
| Cost of Materials Consumed | ₹173.81 Cr | ₹175.78 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹2.63 Cr | -₹4.42 Cr |
| Employee Benefit Expense | ₹68.01 Cr | ₹33.97 Cr |
| Finance Costs | ₹15.31 Cr | ₹6.99 Cr |
| Depreciation & Amortisation | ₹17.15 Cr | - |
| Other Expenses | ₹69.96 Cr | ₹82.43 Cr |
| Total Expenses | ₹341.61 Cr | ₹307.25 Cr |
| Profit Before Exceptional Items & Tax | ₹54.39 Cr | - |
| Exceptional Items | ₹0 | - |
| Profit Before Tax | ₹54.39 Cr | ₹56.97 Cr |
| Total Tax Expense | ₹12.91 Cr | ₹14.55 Cr |
| Net Profit | ₹41.48 Cr | ₹42.42 Cr |
| Other Comprehensive Income | ₹17.73 Lakh | - |
| Total Comprehensive Income | ₹41.66 Cr | - |
| EBITDA (computed) | ₹86.86 Cr | - |
| Basic EPS | ₹40.92 | - |
| Diluted EPS | ₹40.92 | - |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹495.8 Cr | ₹436.23 Cr |
| Non-current Assets | ₹160.64 Cr | ₹105.16 Cr |
| Current Assets | ₹335.16 Cr | ₹331.08 Cr |
| Property, Plant & Equipment | ₹115.37 Cr | ₹80.36 Cr |
| Inventories | ₹74.46 Cr | ₹59.77 Cr |
| Trade Receivables | ₹119.13 Cr | - |
| Cash & Equivalents | ₹124.85 Cr | ₹21.8 Lakh |
| Equity (Net Worth) | ₹244.77 Cr | - |
| Equity Share Capital | ₹10.14 Cr | - |
| Borrowings (Non-current) | ₹133.32 Cr | - |
| Borrowings (Current) | ₹14.48 Cr | - |
| Total Debt (computed) | ₹147.81 Cr | - |
| Current Liabilities | ₹108.14 Cr | ₹102.76 Cr |
| Total Liabilities | ₹251.03 Cr | - |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹37.29 Cr | ₹31.6 Cr |
| Investing Cash Flow | -₹51.39 Cr | -₹35.72 Cr |
| Financing Cash Flow | -₹8.07 Cr | ₹117.94 Cr |
| Capital Expenditure | ₹50.34 Cr | ₹32.52 Cr |
| Free Cash Flow (computed) | -₹13.06 Cr | -₹91.39 Lakh |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹22.18 Cr | ₹113.82 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q4 FY25 |
|---|---|---|---|---|
| Revenue from Operations | ₹93.96 Cr | ₹87.27 Cr | ₹203.59 Cr | ₹182.05 Cr |
| Other Income | ₹2.89 Cr | ₹2.31 Cr | ₹5.98 Cr | ₹4.93 Cr |
| Total Income | ₹96.86 Cr | ₹89.58 Cr | ₹209.57 Cr | ₹186.98 Cr |
| Cost of Materials Consumed | ₹36.78 Cr | ₹32.5 Cr | ₹104.53 Cr | ₹87.96 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹68.85 Lakh | ₹3.54 Cr | -₹5.49 Cr | -₹1.71 Cr |
| Employee Benefit Expense | ₹18.68 Cr | ₹16.82 Cr | ₹19.23 Cr | ₹17.68 Cr |
| Finance Costs | ₹3.94 Cr | ₹4.43 Cr | ₹6.93 Cr | ₹5.16 Cr |
| Depreciation & Amortisation | ₹4.8 Cr | ₹4.39 Cr | - | - |
| Other Expenses | ₹21.51 Cr | ₹17.42 Cr | ₹44.31 Cr | ₹42.33 Cr |
| Total Expenses | ₹85.03 Cr | ₹79.11 Cr | ₹177.48 Cr | ₹158.22 Cr |
| Profit Before Exceptional Items & Tax | ₹11.83 Cr | ₹10.47 Cr | - | - |
| Exceptional Items | ₹0 | ₹0 | - | - |
| Profit Before Tax | ₹11.83 Cr | ₹10.47 Cr | ₹32.09 Cr | ₹24.19 Cr |
| Total Tax Expense | ₹2.78 Cr | ₹1.95 Cr | ₹8.17 Cr | ₹6.21 Cr |
| Net Profit | ₹9.05 Cr | ₹8.52 Cr | ₹23.92 Cr | ₹17.98 Cr |
| attributable to Owners | - | ₹0 | - | - |
| attributable to NCI | - | ₹0 | - | - |
| Other Comprehensive Income | ₹17.73 Lakh | ₹0 | - | - |
| Total Comprehensive Income | ₹9.23 Cr | ₹8.52 Cr | - | - |
| EBITDA (computed) | ₹20.57 Cr | ₹19.3 Cr | - | - |
| Basic EPS | ₹8.93 | ₹8.40 | - | - |
| Diluted EPS | ₹8.93 | ₹8.40 | - | - |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹225.43 Cr | ₹220.2 Cr |
| Other Income | ₹11.14 Cr | ₹6.19 Cr |
| Total Income | ₹236.57 Cr | ₹226.39 Cr |
| Cost of Materials Consumed | ₹121.91 Cr | ₹123.5 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | ₹51.46 Lakh | -₹3.7 Cr |
| Employee Benefit Expense | ₹33.99 Cr | ₹18.95 Cr |
| Finance Costs | ₹11.81 Cr | ₹4.76 Cr |
| Depreciation & Amortisation | ₹9.67 Cr | - |
| Other Expenses | ₹40.47 Cr | ₹50.04 Cr |
| Total Expenses | ₹218.36 Cr | ₹200.98 Cr |
| Profit Before Exceptional Items & Tax | ₹18.21 Cr | - |
| Exceptional Items | ₹0 | - |
| Profit Before Tax | ₹18.21 Cr | ₹20.84 Cr |
| Total Tax Expense | ₹3.88 Cr | ₹5.41 Cr |
| Net Profit | ₹14.33 Cr | ₹15.43 Cr |
| Other Comprehensive Income | ₹16.45 Lakh | - |
| Total Comprehensive Income | ₹14.5 Cr | - |
| EBITDA (computed) | ₹39.69 Cr | - |
| Basic EPS | ₹14.14 | - |
| Diluted EPS | ₹14.14 | - |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹334.96 Cr | ₹316.52 Cr |
| Non-current Assets | ₹116.73 Cr | ₹76.21 Cr |
| Current Assets | ₹218.22 Cr | ₹240.31 Cr |
| Property, Plant & Equipment | ₹69.08 Cr | ₹47.89 Cr |
| Inventories | ₹31.42 Cr | ₹27.44 Cr |
| Trade Receivables | ₹53.81 Cr | - |
| Cash & Equivalents | ₹118.44 Cr | ₹7.33 Lakh |
| Equity (Net Worth) | ₹149.56 Cr | - |
| Equity Share Capital | ₹10.14 Cr | - |
| Borrowings (Non-current) | ₹125.19 Cr | - |
| Borrowings (Current) | ₹5.2 Cr | - |
| Total Debt (computed) | ₹130.39 Cr | - |
| Current Liabilities | ₹54.24 Cr | ₹57.53 Cr |
| Total Liabilities | ₹185.4 Cr | - |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹19.2 Cr | ₹13.47 Cr |
| Investing Cash Flow | -₹31.31 Cr | -₹21.46 Cr |
| Financing Cash Flow | -₹11.44 Cr | ₹118.2 Cr |
| Capital Expenditure | ₹29.17 Cr | ₹20.21 Cr |
| Free Cash Flow (computed) | -₹9.97 Cr | -₹6.73 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | -₹23.55 Cr | ₹110.22 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q4 FY25 |
|---|---|---|---|---|
| Revenue from Operations | ₹54.35 Cr | ₹50.28 Cr | ₹120.81 Cr | ₹102.01 Cr |
| Other Income | ₹2.92 Cr | ₹2.51 Cr | ₹5.72 Cr | ₹4.81 Cr |
| Total Income | ₹57.27 Cr | ₹52.78 Cr | ₹126.52 Cr | ₹106.82 Cr |
| Cost of Materials Consumed | ₹22.72 Cr | ₹24.72 Cr | ₹74.47 Cr | ₹57.1 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹18 Lakh | ₹1.42 Cr | -₹72.52 Lakh | -₹1.07 Cr |
| Employee Benefit Expense | ₹9.25 Cr | ₹8.24 Cr | ₹9.89 Cr | ₹9.88 Cr |
| Finance Costs | ₹2.87 Cr | ₹3.17 Cr | ₹5.76 Cr | ₹4.14 Cr |
| Depreciation & Amortisation | ₹2.74 Cr | ₹2.51 Cr | - | - |
| Other Expenses | ₹12.8 Cr | ₹9.35 Cr | ₹24.93 Cr | ₹25.13 Cr |
| Total Expenses | ₹50.21 Cr | ₹49.41 Cr | ₹118.74 Cr | ₹99.24 Cr |
| Profit Before Exceptional Items & Tax | ₹7.06 Cr | ₹3.37 Cr | - | - |
| Exceptional Items | ₹0 | ₹0 | - | - |
| Profit Before Tax | ₹7.06 Cr | ₹3.37 Cr | ₹7.78 Cr | ₹3.01 Cr |
| Total Tax Expense | ₹1.73 Cr | ₹12.09 Lakh | ₹2.03 Cr | ₹86.86 Lakh |
| Net Profit | ₹5.33 Cr | ₹3.25 Cr | ₹5.75 Cr | ₹2.14 Cr |
| Other Comprehensive Income | ₹16.45 Lakh | ₹0 | - | - |
| Total Comprehensive Income | ₹5.5 Cr | ₹3.25 Cr | - | - |
| EBITDA (computed) | ₹12.67 Cr | ₹9.05 Cr | - | - |
| Basic EPS | ₹5.26 | ₹3.21 | - | - |
| Diluted EPS | ₹5.26 | ₹3.21 | - | - |
Shareholding Pattern of Beta Drugs Limited
As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 59.10%, foreign institutional investors hold 2.95%, domestic institutional investors hold 6.01%, retail and other public shareholders hold 31.93% of Beta Drugs Limited. The company had 5,027 shareholders on record.
| May 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 59.10% | 64.63% | 64.90% | 66.73% | 66.73% | 66.73% |
| Public | 40.90% | 35.37% | 35.10% | 33.27% | 33.27% | 33.27% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Promoters | 64.63% | 66.73% | 66.73% | 66.73% | 66.71% | 66.68% | 66.08% | 69.45% | 68.89% |
| Public | 35.37% | 33.27% | 33.25% | 33.27% | 33.29% | 33.32% | 33.92% | 30.55% | 31.11% |
| Promoter change (YoY, %pts) | -2.10 | +0.00 | +0.00 | +0.02 | +0.03 | +0.60 | -3.37 | +0.56 | - |
Board & Governance of Beta Drugs Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Beta Drugs Limited has 9 directors - 4 independent and 4 executive. The board is chaired by RAHUL BATRA.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| RAHUL BATRA | Executive Director · MD · Chairperson | 2014-08-01 | 1 |
| VARUN BATRA | Executive Director · MD | 2014-08-01 | 1 |
| BALWANT SINGH | Executive Director | 2014-08-01 | 1 |
| ASHUTOSH SHUKLA | Executive Director | 2022-01-20 | 1 |
| MANMOHAN KHANNA | Non-Executive - Independent Director | 2017-07-26 | 0 |
| ROHIT PARTI | Non-Executive - Independent Director | 2017-07-26 | 0 |
| MONICA JAIN | Non-Executive - Independent Director | 2025-02-05 | 0 |
| LALIT KUMAR WATTS | Non-Executive - Independent Director | 2025-02-05 | 0 |
| SANJAY SEHGAL | Non-Executive - Independent Director | 2024-11-27 | 0 |
| AJAY MAHIPAL | Non-Executive - Non Independent Director | 2024-11-27 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | RAHUL BATRA, ROHIT PARTI, MANMOHAN KHANNA (Chairperson) |
| Nomination and remuneration committee | RAHUL BATRA, ROHIT PARTI, MANMOHAN KHANNA (Chairperson), SANJAY SEHGAL |
| Stakeholders Relationship Committee | RAHUL BATRA, ROHIT PARTI, MANMOHAN KHANNA (Chairperson) |
| Corporate Social Responsibility Committee | RAHUL BATRA (Chairperson), VARUN BATRA, ROHIT PARTI |
Group Structure of Beta Drugs Limited
Beta Drugs Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Beta Drugs Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Adley Lab Limited | U24231PB1992PLC051220 | - |
| Adley Formulations Private Limited | U24303HR2018PTC076347 | - |
| Beta Reseach Private Limited | U24303HR2022PTC104598 | - |
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Beta Drugs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Sep 2025 | Sidbi | ₹1.42 Cr | Open |
| 02 Jul 2025 | Sidbi | ₹1.5 Cr | Open |
| 15 May 2025 | Others | ₹7 Cr | Open |
| 29 Mar 2025 | Axis Bank Limited | ₹1.98 Cr | Open |
| 27 Mar 2025 | Sidbi | ₹3 Cr | Open |
Total charge records: 47 View all charges
Employees and EPFO Compliance at Beta Drugs Limited
Beta Drugs Limited has a workforce of 382 employees as of Mar 31, 2025.
Employee and EPFO history for Beta Drugs Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Beta Drugs Limited
GST registrations and filing compliance for Beta Drugs Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Beta Drugs Limited
Credit ratings, litigation, and regulatory alerts for Beta Drugs Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Beta Drugs Limited
MSME payment history for Beta Drugs Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Beta Drugs Limited
Corporate group structure for Beta Drugs Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Beta Drugs Limited
MCA filings and documents for Beta Drugs Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Beta Drugs Limited
Frequently Asked Questions about Beta Drugs Limited
Beta Drugs Limited is an active public limited company in the pharma sector based in Baddi, Himachal Pradesh, India. It was incorporated on 21 September 2005 (21+ years old) and is registered under CIN L24230HP2005PLC028969. Listed on NSE: BETA. The company has 382 employees.
Beta Drugs Limited reported revenue of ₹384.83 Cr for FY 2026 (up 6.2% YoY) based on consolidated NSE filings.
The current directors of Beta Drugs Limited are:
- Balwant Singh - Whole-Time Director
- Rohit Parti - Director
- Manmohan Khanna - Director
- Varun Batra - Managing Director
- Rahul Batra - Managing Director
- Ashutosh Shukla - Whole-Time Director
- Monica Jain - Director
- Lalit Kumar Watts - Director
- Sanjay Sehgal - Director
- Ajay Mahipal - Director
The primary industry of Beta Drugs Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Beta Drugs Limited is listed on NSE with symbol BETA.
Beta Drugs Limited can be reached at the registered office: Village Nandpur, Baddi, Himachal Pradesh, India – 174101, or through the website betadrugslimited.com.